Kymera Therapeutics (NASDAQ:KYMR) Stock Price Down 6.2% - Time to Sell?

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) traded down 6.2% during mid-day trading on Tuesday . The stock traded as low as $31.70 and last traded at $31.61. 160,447 shares were traded during trading, a decline of 69% from the average session volume of 513,364 shares. The stock had previously closed at $33.70.

Analyst Upgrades and Downgrades

KYMR has been the subject of several research analyst reports. HC Wainwright upped their price target on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Citigroup started coverage on Kymera Therapeutics in a research note on Thursday, March 13th. They set a "buy" rating and a $52.00 target price for the company. Wells Fargo & Company upgraded Kymera Therapeutics from an "equal weight" rating to an "overweight" rating and lifted their target price for the stock from $38.00 to $57.00 in a report on Monday, December 2nd. BMO Capital Markets began coverage on shares of Kymera Therapeutics in a report on Friday, December 6th. They set a "market perform" rating and a $55.00 price objective for the company. Finally, Stephens reiterated an "overweight" rating and set a $60.00 target price on shares of Kymera Therapeutics in a report on Tuesday, January 21st. Three analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Kymera Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $56.36.

Remove Ads

Kymera Therapeutics Trading Down 1.9 %

The firm has a market cap of $1.92 billion, a price-to-earnings ratio of -12.66 and a beta of 2.22. The stock has a 50-day moving average of $35.86 and a two-hundred day moving average of $41.77.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.12). The firm had revenue of $7.39 million during the quarter, compared to the consensus estimate of $14.81 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. Sell-side analysts expect that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Insider Buying and Selling

In other Kymera Therapeutics news, insider Ellen Chiniara sold 2,241 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $68,238.45. Following the completion of the transaction, the insider now directly owns 80,085 shares in the company, valued at $2,438,588.25. The trade was a 2.72 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Jeremy G. Chadwick sold 1,383 shares of the business's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $42,112.35. Following the sale, the chief operating officer now owns 67,800 shares in the company, valued at $2,064,510. This represents a 2.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 13,788 shares of company stock valued at $455,202. Company insiders own 15.82% of the company's stock.

Hedge Funds Weigh In On Kymera Therapeutics

Several large investors have recently modified their holdings of the business. Price T Rowe Associates Inc. MD boosted its holdings in Kymera Therapeutics by 3.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,870,333 shares of the company's stock valued at $276,395,000 after acquiring an additional 224,859 shares during the period. Wellington Management Group LLP grew its holdings in shares of Kymera Therapeutics by 14.9% during the fourth quarter. Wellington Management Group LLP now owns 5,307,326 shares of the company's stock valued at $213,514,000 after buying an additional 688,967 shares during the last quarter. Avoro Capital Advisors LLC raised its position in Kymera Therapeutics by 14.4% in the 4th quarter. Avoro Capital Advisors LLC now owns 5,150,000 shares of the company's stock worth $207,184,000 after buying an additional 650,000 shares during the last quarter. FMR LLC boosted its stake in shares of Kymera Therapeutics by 5.8% in the 3rd quarter. FMR LLC now owns 5,109,141 shares of the company's stock worth $241,816,000 after buying an additional 282,301 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in Kymera Therapeutics by 2.8% during the fourth quarter. Vanguard Group Inc. now owns 4,887,312 shares of the company's stock valued at $196,617,000 after buying an additional 133,546 shares during the period.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.